Peripheral Neuronal Mechanism of Itch: Histamine and Itch

ITCH: Mechanisms and Treatment

Volumn , Issue , 2014, Pages 143-192

  Thurmond, Robin L ^a   Kazerouni, Kayvan ^a   Chaplan, Sandra R ^a   Greenspan, Andrew J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85137469932     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16573-14     Document Type: Chapter

References (416)

1. Abdelaziz MM, Devalia JL, Khair OA, Bayram H, Prior AJ and Davies RJ (1998) Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 101: 410-420.
2. Abel JJ and Kubota S (1919) Presence of histamine (4-imidozoleethylamine) in the hypophy-sis cerebri and other tissues of the body and its occurrence among the hydrolytic decom-position products of proteins. J. Pharmacol. 13: 243-300.
3. Abelson MB (1998) Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann. Allergy Asthma Immunol. 81: 211-218.
4. Abelson MB, Allansmith MR and Friedlaender MH (1980) Effects of topically applied occular decongestant and antihistamine. Am. J. Ophthalmol. 90: 254-257.
5. Abelson MB, Chambers WA and Smith LM (1990) Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol. 108: 84-88.
6. Abelson MB, George MA and Smith LM (1995) Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 102: 310-316.
7. Abelson MB and Kaplan AP (2002) A randomized, double-blind, placebo-controlled compari-son of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combina-tion in the human conjunctival allergen challenge model. Clin. Ther. 24: 445-456.
8. Abelson MB and Lanier RQ (1999) The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Acta Ophthalmol. Scand. Suppl. 228: 53-56.
9. Abelson MB and Smith LM (1988) Levocabastine. Evaluation in the histamine and compound 48/80 models of ocular allergy in humans. Ophthalmology 95: 1494-1497.
10. Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ and McNamara TR (2009) Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospec-tive, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin. Ther. 31: 1908-1921.
11. Abelson MB and Udell IJ (1981) H2-receptors in the human ocular surface. Arch. Ophthalmol. 99: 302-304.
12. Abelson MB and Welch DL (2000) An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol. Scand. Suppl. 230: 60-63.
13. Aguilar AJ (2000) Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketoti-fen fumarate. Acta Ophthalmol. Scand. Suppl. 230: 52-55.
14. Ahern K, Gilmore ES and Poligone B (2012) Pruritus in cutaneous T-cell lymphoma: A review. J. Am. Acad. Dermatol. 67: 760-768.
15. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q et al. (2006) Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J. Allergy Clin. Immunol. 118: 152-169.
16. Amano T, Takeda T, Yano H and Tamura T (2007) Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice. Br. J. Dermatol. 156: 906-912.
17. Andrew D and Craig AD (2001) Spinothalamic lamina I neurons selectively sensitive to hista-mine: A central neural pathway for itch. Nat. Neurosci. 4: 72-77.
18. Anolik R (2008) Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of sea-sonal allergic rhinitis. Ann. Allergy Asthma Immunol. 100: 264-271.
19. Appl H, Holzammer T, Dove S, Haen E, Strasser A and Seifert R (2012) Interactions of recom-binant human histamine H1, H2, H3, and H4 receptors with 34 antidepressants and antipsychotics. Naunyn-Schmiedeberg’s Arch. Pharmacol. 385: 145-170.
20. Arrang JM, Garbarg M and Schwartz JC (1983) Autoinhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 302: 832-837.
21. Arrang JM, Garbarg M, Tam TQ, My DTT, Yeramian E and Schwartz JC (1985) Actions of betahistine at histamine receptors in the brain. Eur. J. Pharmacol. 111: 73-84.
22. Ash ASF and Schild JO (1966) Receptors mediating some action of histamine. Br. J. Pharmacol. 27: 427-439.
23. Ashford CA, Heller H and Smart GA (1949) Effect of antihistamine substances on gastric secretion in man. Br. J. Pharmacol. Chemother. 4: 157-161.
24. Bachs L, Pares A, Elena M, Piera C and Rodes J (1989) Comparison of rifampicin with pheno-barbitone for treatment of pruritus in biliary cirrhosis. Lancet 1: 574-576.
25. Bain WA (1951) Evaluation of drugs in man, with special reference to antihistamines. Analyst 76: 573-579.
26. Bain WA, Broadbent JL and Warin RP (1949) Comparison of anthisan (mepyramine maleate) and phenergan as histamine antagonists. Lancet 257: 47-52.
27. Bakker RA, Schoonus SBJ, Smit MJ, Timmerman H and Leurs R (2001) Histamine H1-receptor activation of nuclear factor-kB: Roles for Gbg- and Gaq/11-subunits in constitutive and agonist-mediated signaling. Mol. Pharmacol. 60: 1133-1142.
28. Barger G and Dale HH (1910) 4-β-Aminoethylglyoxaline (β-Aminazolylethylamine) and the other active principles of ergot. J. Chem. Soc., Trans. 97: 2592-2595.
29. Barger G and Dale HH (1911) 4-β-Aminoethylglyoxaline (β-aminazolylethylamine) and the other active principles of wrgot. Proc. Chem. Soc., London. 26:327.
30. Bäumer W, Wendorff S, Gutzmer R, Werfel T, Dijkstra D, Chazot P, Stark H and Kietzmann M (2008) Histamine H4 receptors modulate dendritic cell migration through skin-immu-nomodulatory role of histamine. Allergy 63: 1387-1394.
31. Bell JK, McQueen DS and Rees JL (2004) Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in BalbC mice. Br. J. Pharmacol. 142: 374-380.
32. Bende M and Pipkorn U (1987) Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Allergy 42: 512-515.
33. Benninger M, Farrar JR, Blaiss M, Chipps B, Ferguson B, Krouse J, Marple B, Storms W and Kaliner M (2010) Evaluating approved medications to treat allergic rhinitis in the United States: An evidence-based review of efficacy for nasal symptoms by class. Ann. Allergy Asthma Immunol. 104: 13-29.
34. Bergasa NV and Jones EA (1991) Management of the pruritus of cholestasis: Potential role of opiate antagonists. Am. J. Gastroenterol. 86: 1404-1412.
35. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH and Jones EA (1992) A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102: 544-549.
36. Berger W, Hampel F, Jr., Bernstein J, Shah S, Sacks H and Meltzer EO (2006) Impact of azelas-tine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 97: 375-381.
37. Berger WE, Schenkel EJ and Mansfield LE (2002) Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol. 89: 485-491.
38. Bernstein DI, Creticos PS, Busse WW, Cohen R, Graft DF, Howland WC, Lumry WR et al. (1996) Comparison of triamcinolone acetonide nasal inhaler with astemizole in the treatment of ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 97: 749-755.
39. Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R and Mason J (1997) Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 79: 443-448.
40. Best CH, Dale HH, Dudley HW and Thorpe WV (1927) The nature of the vaso-dilator con-stituents of certain tissue extracts. J. Physiol. 62: 397-417.
41. Bickford RG (1937) Experiments relating to the itch sensation, it’s peripheral mechanism, and central pathways. Clin. Sci. 3: 377-386.
42. Bielory L, Lien KW and Bigelsen S (2005) Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 65: 215-228.
43. Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewicz M, Yao L, Storey H, LeCiel C, Harder B and Gross JA (2006) IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 117: 418-425.
44. Black JW, Duncan WAM, Durant CJ, Ganellin CR and Parsons EM (1972) Definition and antagonism of histamine H2-receptors. Nature 236: 385-390.
45. Bonadonna P, Lombardi C, Senna G, Canonica GW, Passalacqua G, Breneman D, Bronsky EA et al. (2003) Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J. Am. Acad. Dermatol. 49: 714-716.
46. Bongers G, de Esch I and Leurs R (2010) Molecular pharmacology of the four histamine receptors. Adv. Exp. Med. Biol. 709: 11-19.
47. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H and Erbek SS (2009) Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: A placebo-controlled environmental trial. Acta Ophthalmol. 87: 549-554.
48. Bovet D and Staub AM (1937) Protective action of some phenolic ethers in histamine intoxica-tion. C. R. Seances Soc. Biol. Fil. 124: 547-549.
49. Boyle J, Eriksson M, Stanley N, Fujita T and Kumagi Y (2006) Allergy medication in Japanese volunteers: Treatment effect of single doses on nocturnal sleep architecture and next day residual effects. Curr. Med. Res. Opin. 22: 1343-1351.
50. Breneman DL (1996) Cetirizine versus hydroxyzine and placebo in chronic idiopathic urti-caria. Ann. Pharmacother. 30: 1075-1079.
51. Broadbent JL (1953) Observations on itching produced by cowhage, and on the part played by histamine as a mediator of the itch sensation. Br. J. Pharmacol. Chemother. 8: 263-270.
52. Broadbent JL (1955) Observations on histamine-induced pruritus and pain. Br. J. Pharmacol. Chemother. 10: 183-185.
53. Brody I (1984) Mast cell degranulation in the evolution of acute eruptive guttate psoriasis vulgaris. J. Invest. Dermatol. 82: 460-464.
54. Brooks CD, Nelson A, Parzyck R and Maile MH (1981) Protective effect of hydroxyzine and phenylpropanolamine in the challenged allergic nose. Ann. Allergy 47: 316-319.
55. Brostoff J, Fitzharris P, Dunmore C, Theron M and Blondin P (1996) Efficacy of mizolastine, a new antihistamine, compared with placebo in the treatment of chronic idiopathic urti-caria. Allergy 51: 320-325.
56. Buckland KF, Williams TJ and Conroy DM (2003) Histamine induces cytoskeletal changes in human eosinophils via the H4 receptor. Br. J. Pharmacol. 140: 1117-1127.
57. Buddenkotte J, Maurer M and Steinhoff M (2010) Histamine and antihistamines in atopic dermatitis. Adv. Exp. Med. Biol. 709: 73-80.
58. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U and Bousquet J (2012) A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 129:1282-1289 e1210.
59. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, Simons FE et al. (2003) First do no harm: Managing antihistamine impairment in patients with allergic rhinitis. J. Allergy Clin. Immunol. 111:S835-S842.
60. Celice J, Perrault M and Durel P (1942) Utilisation clinique des antihistaminiques de synthese. Bull. Mem. Soc. Med. Hop. Paris 21-22:284-288.
61. Chang RSL, Vihn TT and Snyder SH (1979) Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J. Neurochem. 32: 1653-1663.
62. Chaufour S, Caplain H, Lilienthal N, L’Heritier C, Deschamps C, Dubruc C and Rosenzweig P (1999) Study of cardiac repolarization in healthy volunteers performed with mizolas-tine, a new H1-receptor antagonist. Br. J. Clin. Pharmacol. 47: 515-520.
63. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, Holgate ST and Zuberbier T (2010) Risk of first-generation H(1)-antihistamines: A GA(2)LEN position paper. Allergy 65: 459-466.
64. Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M and Canonica GW (1997) Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin. Exp. Allergy 27: 182-191.
65. Clough GF, Boutsiouki P and Church MK (2001) Comparison of the effects of levocetiri-zine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 56: 985-988.
66. Code CF (1945) A discussion of benadryl as an antihistamine substance. Proc. Staff Meet. Mayo Clin. 20: 439-445.
67. Coge F, Guenin S-P, Audinot V, Renouard-Try A, Beauverger P, Macia C, Ouvry C et al. (2001) Genomic organization and characterization of splice variants of the human hista-mine H3 receptor. Biochem. J. 355: 279-288.
68. Connelly WM, Shenton FC, Lethbridge N, Leurs R, Waldvogel HJ, Faull RLM, Lees G and Chazot PL (2009) The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br. J. Pharmacol. 157: 55-63.
69. Cormia FE (1952) Experimental histamine pruritis. I. Influence of physical and psychological factors on reactivity. J. Invest. Dermatol. 19: 21-34.
70. Cormia FE and Dougherty JW (1960) Proteolytic activity in development of pain and itching. Cutaneous reactions to bradykinin and kallikrein. J. Invest. Dermatol. 35: 21-26.
71. Cormia FE and Kuykendall V (1954) Experimental histamine pruritus. III. Influence of drugs on the itch threshold. A.M.A. Arch. Dermatol. Syphilol. 69: 206-218.
72. Coulie PJ, Ghys L and Rihoux JP (1991) Histamine-induced wheal, flare, and pruritus: Inhibition by cetirizine, terfenadine, and placebo. Drug Dev. Res. 23: 269-274.
73. Cowden JM, Zhang M, Dunford PJ and Thurmond RL (2010) The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J. Invest. Dermatol. 130: 1023-1033.
74. Craft TM (1986) Torsade de pointes after astemizole overdose. Br. Med. J. 292:660.
75. Crampton HJ (2002) A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symp-toms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. Clin. Ther. 24: 1800-1808.
76. Crampton HJ (2003) Comparison of ketotifen fumarate ophthalmic solution alone, deslorata-dine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: A double-masked, placebo- and active-controlled trial. Clin. Ther. 25: 1975-1987.
77. Curtis AC and Owens BB (1945) Beta dimethylaminoethyl benzhydryl ether hydrochloride (benadryl) in treatment of urticaria. Arch. Derm. Syphilol. 52: 239-242.
78. Cynamon HA, Andres JM and Iafrate RP (1990) Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 98: 1013-1016.
79. D’Arienzo PA, Leonardi A and Bensch G (2002) Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 24: 409-416.
80. Dale HH (1929) Croonian lectures on some chemical factors in the control of the circulation. Lancet 213: 1233-1237.
81. Dale HH (1953) Adventures in Physiology. New York: Macmillan.
82. Dale HH and Laidlaw PP (1911) The physiological action of β-iminazolylethylamine. J. Physiol. 41: 318-344.
83. Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A and McQuade B (2012) The effi-cacy and tolerability of two novel H1/H3 receptor antagonists in seasonal allergic rhini-tis. Int. Arch. Allergy Immunol. 158: 84-98.
84. Darsow U, Drzezga A, Frisch M, Munz F, Weilke F, Bartenstein P, Schwaiger M and Ring J (2000) Processing of histamine-induced itch in the human cerebral cortex: A correlation analysis with dermal reactions. J. Invest. Dermatol. 115: 1029-1033.
85. Darsow U, Ring J, Scharein E and Bromm B (1996) Correlations between histamine-induced wheal, flare and itch. Arch. Dermatol. Res. 288: 436-441.
86. Davidson S, Zhang X, Khasabov SG, Simone DA and Giesler GJ, Jr. (2009) Relief of itch by scratching: State-dependent inhibition of primate spinothalamic tract neurons. Nat. Neurosci. 12: 544-546.
87. Davidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA and Giesler GJ, Jr. (2007) The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J. Neurosci. 27: 10007-10014.
88. Davies MG and Greaves MW (1980) Sensory responses of human skin to synthetic histamine analogs and histamine. Br. J. Clin. Pharmacol. 9: 461-465.
89. Davies MG, Marks R, Horton RJ and Storari FE (1979) The efficacy of histamine antagonists as antipruritics in experimentally induced pruritus. Arch. Dermatol. Res. 266: 117-120.
90. Dawn A and Yosipovitch G (2006) Treating itch in psoriasis. Dermatol. Nurs. 18: 227-233.
91. De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE and Luyten WHML (1993) Genomic cloning, heterologous expression and pharmacological char-acterization of a human histamine H1 receptor. Biochem. Biophys. Res. Commun. 197: 1601-1608.
92. Decourt P (1942) Action de bases antagonistes de l’histamine sur quelques maladies liees a des reactions d’hypersensibilite. Bull. Mem. Soc. Med. Hop. Paris 58: 265-266.
93. Del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J and Valero AL (2006) Comparative pharmacology of the H1 antihistamines. J. Investig. Allergol. Clin. Immunol. 16 Suppl 1:3-12.
94. Demierre MF, Gan S, Jones J and Miller DR (2006) Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 107: 2504-2511.
95. Deml K-F, Beermann S, Neumann D, Strasser A and Seifert R (2009) Interactions of hista-mine H1-receptor agonists and antagonists with the human histamine H4-receptor. Mol. Pharmacol. 76: 1019-1030.
96. Denham KJ, Boutsiouki P, Clough GF and Church MK (2003) Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm. Res. 52: 424-427.
97. Desai P and Thurmond RL (2011) Histamine H4 receptor activation enhances LPS-induced IL-6 production in mast cells via ERK and PI3K activation. Eur. J. Immunol. 41: 1764-1773.
98. Diepgen TL (2002) Long-term treatment with cetirizine of infants with atopic dermatitis: A multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunol. 13: 278-286.
99. Dijkstra D, Stark H, Chazot PL, Shenton FC, Leurs R, Werfel T and Gutzmer R (2008) Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J. Invest. Dermatol. 128: 1696-1703.
100. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS et al. (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 5: 752-760.
101. Discepola M, Deschenes J and Abelson M (1999) Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol. Scand. Suppl. 228: 43-46.
102. Doeglas HM (1975) Reactions to aspirin and food additives in patients with chronic urticaria, including the physical urticarias. Br. J. Dermatol. 93: 135-144.
103. Drake LA, Fallon JD and Sober A (1994) Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group. J. Am. Acad. Dermatol. 31: 613-616.
104. Drzezga A, Darsow U, Treede RD, Siebner H, Frisch M, Munz F, Weilke F, Ring J, Schwaiger M and Bartenstein P (2001) Central activation by histamine-induced itch: Analogies to pain processing: A correlational analysis of O-15 H2O positron emission tomography studies. Pain 92: 295-305.
105. Dubertret L, Murrieta Aguttes M and Tonet J (1999) Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: Results of the MILOR Study. J. Eur. Acad. Dermatol. Venereol. 12: 16-24.
106. DuBuske LM (1999) Second-generation antihistamines: The risk of ventricular arrhythmias. Clin. Ther. 21: 281-295.
107. Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D and Thurmond RL (2007) Histamine H4 receptor antagonists are superior to traditional antihistamines in the atten-uation of experimental pruritus. J. Allergy Clin. Immunol. 119: 176-183.
108. Eda R, Townley RG and Hopp RJ (1994) Effect of terfenadine on human eosinophil and neu-trophil chemotactic response and generation of superoxide. Ann. Allergy 73: 154-160.
109. Eglezos A, Lecci A, Santicioli P, Giuliani S, Tramontana M, Del Bianco E and Maggi CA (1992) Activation of capsaicin-sensitive primary afferents in the rat urinary bladder by compound 48/80: A direct action on sensory nerves? Arch. Int. Pharmacodyn. Ther. 315: 96-109.
110. Elmariah SB and Lerner EA (2011) Topical therapies for pruritus. Semin. Cutan. Med. Surg. 30: 118-126.
111. Eppinger H (1913) Wien. Med. Wochenschr. 23:1414.
112. Eriks JC, Van DGH and Timmerman H (1993) New activation model for the histamine H2 receptor, explaining the activity of the different classes of histamine H2 receptor ago-nists. Mol. Pharmacol. 44: 886-894.
113. Ernstene AC and Banks BM (1933) Use of histamine in the treatment of pruritus. J. Am. Med. Assoc. 100: 328-330.
114. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB et al. (2003) Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J. Pharmacol. Exp. Ther. 305: 887-896.
115. Fedorowicz Z, van ZEJ and Hu N (2012) Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst. Rev. 3:CD008596.
116. Feinberg SM and Friedlaender S (1945) Relief of dermographism and other urticarias of hista-mine origin by a synthetic benzhydryl alkamine ether. J. Allergy 16: 296-298.
117. Fjellner B and Haegermark O (1981) Studies on pruritogenic and histamine-releasing effects of some putative peptide neurotransmitters. Acta Derm. Venereol. 61: 245-250.
118. Fjellner B and Hagermark O (1985) Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin. Acta Derm. Venereol. 65: 409-412.
119. Francos GC, Kauh YC, Gittlen SD, Schulman ES, Besarab A, Goyal S and Burke JF, Jr. (1991) Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int. J. Dermatol. 30: 884-889.
120. Furue M, Terao H and Koga T (2001) Effects of cetirizine and epinastine on the skin response to histamine iontophoresis. J. Dermatol. Sci. 25: 59-63.
121. Galandrin S, Oligny-Longpré G and Bouvier M (2007) The evasive nature of drug efficacy: Implications for drug discovery. Trends Pharmacol. Sci. 28: 423-430.
122. Gallois-Bernos AC and Thurmond RL (2012) Alcaftadine, a new antihistamine with combined antagonist activity at histamine H1, H2, and H4 receptors. J. Receptor Ligand Channel Res. 2012: 9-20.
123. Gantz I, Munzert G, Tashiro T, Schaffer M, Wang L, DelValle J and Yamada T (1991) Molecular cloning of the human histamine H2 receptor. Biochem. Biophys. Res. Commun. 178: 1386-1392.
124. Ganz M, Koll E, Gausche J, Detjen P and Orfan N (2003) Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: A real-world comparison of efficacy and ocular comfort. Adv. Ther. 20: 79-91.
125. Gbahou F, Vincent L, Humbert-Claude M, Tardivel-Lacombe J, Chabret C and Arrang J-M (2006) Compared pharmacology of human histamine H3 and H4 receptors: Structure-activity relationships of histamine derivatives. Br. J. Pharmacol. 147: 744-754.
126. Gehanno P and Desfougeres JL (1997) Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy 52: 445-450.
127. Ghent CN and Carruthers SG (1988) Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 94: 488-493.
128. Giede C, Metzenauer P, Petzold U and Ellers-Lenz B (2000) Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr. Med. Res. Opin. 16: 153-163.
129. Gillard M, Van Der Perren C, Moguilevsky N, Massingham R and Chatelain P (2002) Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: Contribution of Lys(191) and Thr(194). Mol. Pharmacol. 61: 391-399.
130. Gillen MS, Miller B, Chaikin P and Morganroth J (2001) Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br. J. Clin. Pharmacol. 52: 201-204.
131. Gimenez-Arnau A, Izquierdo I and Maurer M (2009) The use of a responder analysis to iden-tify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. J. Eur. Acad. Dermatol. Venereol. 23: 1088-1091.
132. Gimenez-Arnau A, Pujol RM, Ianosi S, Kaszuba A, Malbran A, Poop G, Donado E, Perez I, Izquierdo I and Arnaiz E (2007) Rupatadine in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled multicentre study. Allergy 62: 539-546.
133. Gittlen SD, Schulman ES and Maddrey WC (1990) Raised histamine concentrations in chronic cholestatic liver disease. Gut 31: 96-99.
134. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R and Kavanaugh A (2009) Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 373: 633-640.
135. Govoni M, Bakker RA, van de Wetering I, Smit MJ, Menge WM, Timmerman H, Elz S, Schunack W and Leurs R (2003) Synthesis and pharmacological identification of neu-tral histamine H1-receptor antagonists. J. Med. Chem. 46: 5812-5824.
136. Graham DT, Goodell H and Wolff HG (1951) Neural mechanisms involved in itch, itchy skin, and tickle sensations. J. Clin. Invest. 30: 37-49.
137. Greaves MW (1995) Chronic urticaria. N. Engl. J. Med. 332: 1767-1772.
138. Greiner JV, Edwards-Swanson K and Ingerman A (2011) Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin. Ophthalmol. 5: 87-93.
139. Greiner JV and Minno G (2003) A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. Clin. Ther. 25: 1988-2005.
140. Gschwandtner M, Mommert S, Koether B, Werfel T and Gutzmer R (2011a) The histamine H4 receptor is highly expressed on plasmacytoid dendritic cells in psoriasis and his-tamine regulates their cytokine production and migration. J. Invest. Dermatol. 131: 1668-1676.
141. Gschwandtner M, Schaekel K, Werfel T and Gutzmer R (2011b) Histamine H4 receptor acti-vation on human slan-dendritic cells down-regulates their pro-inflammatory capacity. Immunology 132: 49-56.
142. Guerra L, Vincenzi C, Marchesi E, Tosti A, Pretto E, Bassi R, Fubbian PR and De Costanza F (1994) Loratadine and cetirizine in the treatment of chronic urticaria. J. Eur. Acad. Dermatol. Venereol. 3: 148-152.
143. Gutzmer R, Diestel C, Mommert S, Koether B, Stark H, Wittmann M and Werfel T (2005) Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates che-motaxis in human monocyte-derived dendritic cells. J. Immunol. 174: 5224-5232.
144. Gutzmer R, Mommert S, Gschwandtner M, Zwingmann K, Stark H and Werfel T (2009) The histamine H4 receptor is functionally expressed on TH2 cells. J. Allergy Clin. Immunol. 123: 619-625.
145. Haas HL, Sergeeva OA and Selbach O (2008) Histamine in the nervous system. Physiol. Rev. 88: 1183-1241.
146. Hagermark O (1973) Influence of antihistamines, sedatives, and aspirin on experimental itch. Acta Derm. Venereol. 53: 363-368.
147. Hagermark O (1974) Studies on experimental itch induced by kallikrein and bradykinin. Acta Derm. Venereol. 54: 397-400.
148. Hagermark O, Hokfelt T and Pernow B (1978) Flare and itch induced by substance P in human skin. J. Invest. Dermatol. 71: 233-235.
149. Hagermark O, Rajka G and Bergvist U (1972) Experimental itch in human skin elicited by rat mast cell chymase. Acta Derm. Venereol. 52: 125-128.
150. Hagermark O, Strandberg K and Gronneberg R (1979) Effects of histamine receptor antago-nists on histamine-induced responses in human skin. Acta Derm. Venereol. 59: 297-300.
151. Halpern BN (1942) Synthetic antihistamine substances. Arch. Int. Pharmacodyn. Ther. 68: 339-408.
152. Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y and Georges G (2003) Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 91: 354-361.
153. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W and Sacks H (2010) Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann. Allergy Asthma Immunol. 105: 168-173.
154. Handa S, Dogra S and Kumar B (2004) Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J. Dermatolog. Treat. 15: 55-57.
155. Handwerker HO, Forster C and Kirchhoff C (1991) Discharge patterns of human C-fibers induced by itching and burning stimuli. J. Neurophysiol. 66: 307-315.
156. Harada M, Terai M and Maeno H (1983) Effect of a new potent H2-receptor antagonist 3[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]-N2-sulfamoylpropionami-dine (YM-11170) on gastric mucosal histamine-sensitive adenylate cyclase from guinea pig. Biochem. Pharmacol. 32: 1635-1640.
157. Havas TE, Cole P, Parker L, Oprysk D and Ayiomamitis A (1986) The effects of combined H1 and H2 histamine antagonists on alterations in nasal airflow resistance induced by topi-cal histamine provocation. J. Allergy Clin. Immunol. 78: 856-860.
158. Herde L, Forster C, Strupf M and Handwerker HO (2007) Itch induced by a novel method leads to limbic deactivations a functional MRI study. J. Neurophysiol. 98: 2347-2356.
159. Herndon JH, Jr. (1975) Itching: The pathophysiology of pruritus. Int. J. Dermatol. 14: 465-484.
160. Herring WJ, Wilens TE, Adler LA, Baranak C, Liu K, Snavely DB, Lines CR and Michelson D (2012) Randomized controlled study of the histamine h3 inverse agonist mk-0249 in adult attention-deficit/hyperactivity disorder. J. Clin. Psychiatry. 73:e891-e898.
161. Heyer G, Koppert W, Martus P and Handwerker HO (1998) Histamine and cutaneous noci-ception: histamine-induced responses in patients with atopic eczema, psoriasis and urti-caria. Acta Derm. Venereol. 78: 123-126.
162. Hilberg O (1995) Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge. Allergy 50: 683-688.
163. Hilberg O, Grymer LF and Pedersen OF (1995) Nasal histamine challenge in nonallergic and allergic subjects evaluated by acoustic rhinometry. Allergy 50: 166-173.
164. Hindmarch I, Shamsi Z, Stanley N and Fairweather DB (1999) A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br. J. Clin. Pharmacol. 48: 200-206.
165. Hofstra CL, Desai PJ, Thurmond RL and Fung-Leung W-P (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther. 305: 1212-1221.
166. Horak F, Berger UE, Menapace R, Toth J, Stubner PU and Marks B (1998) Dose-dependent protection by azelastine eye drops against pollen-induced allergic conjunctivitis. A double-blind, placebo-controlled study. Arzneimittelforschung. 48: 379-384.
167. Horsmanheimo L, Harvima IT, Harvima RJ, Brummer-Korvenkontio H, Francois G and Reunala T (1996) Histamine and leukotriene C4 release in cutaneous mosquito-bite reactions. J. Allergy Clin. Immunol. 98: 408-411.
168. Hosogi M, Schmelz M, Miyachi Y and Ikoma A (2006) Bradykinin is a potent pruritogen in atopic dermatitis: A switch from pain to itch. Pain 126: 16-23.
169. Hossen MA, Inoue T, Shinmei Y, Fujii Y, Watanabe T and Kamei C (2006) Role of substance P on histamine H3 antagonist-induced scratching behavior in mice. J. Pharmacol. Sci. 100: 297-302.
170. Hossen MA, Sugimoto Y, Kayasuga R and Kamei C (2003) Involvement of histamine H3 receptors in scratching behavior in mast cell-deficient mice. Br. J. Dermatol. 149: 17-22.
171. Hough LB (2001) Genomics meets histamine receptors: New subtypes, new receptors. Mol. Pharmacol. 59: 415-419.
172. Howarth PH, Stern MA, Roi L, Reynolds R and Bousquet J (1999) Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J. Allergy Clin. Immunol. 104: 927-933.
173. Hsieh JC, Hagermark O, Stahle-Backdahl M, Ericson K, Eriksson L, Stone-Elander S and Ingvar M (1994) Urge to scratch represented in the human cerebral cortex during itch. J. Neurophysiol. 72: 3004-3008.
174. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J et al. (2012) Consensus guidelines for the management of plaque psoriasis. Arch. Dermatol. 148: 95-102.
175. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A and Stockis A (2007) Levocetirizine does not prolong the QT/QTc interval in healthy subjects: Results from a thorough QT study. Eur. J. Clin. Pharmacol. 63: 1011-1017.
176. Ikawa Y, Shiba K, Ohki E, Mutoh N, Suzuki M, Sato H and Ueno K (2008) Comparative study of histamine H4 receptor expression in human dermal fibroblasts. J. Toxicol. Sci. 33: 503-508.
177. Ikoma A (2009) Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: Mechanisms and management of itch in atopic dermatitis. J. Pharmacol. Sci. 110: 265-269.
178. James IG, Campbell LM, Harrison JM, Fell PJ, Ellers-Lenz B and Petzold U (2003) Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr. Med. Res. Opin. 19: 313-320.
179. Johanek LM, Meyer RA, Friedman RM, Greenquist KW, Shim B, Borzan J, Hartke T, LaMotte RH and Ringkamp M (2008) A role for polymodal C-fiber afferents in nonhistaminergic itch. J. Neurosci. 28: 7659-7669.
180. Johanek LM, Meyer RA, Hartke T, Hobelmann JG, Maine DN, LaMotte RH and Ringkamp M (2007) Psychophysical and physiological evidence for parallel afferent pathways medi-ating the sensation of itch. J. Neurosci. 27: 7490-7497.
181. Johnson HH, Jr., DeOreo GA, Lascheid WP and Mitchell F (1960) Skin histamine levels in chronic atopic dermatitis. J. Invest. Dermatol. 34: 237-238.
182. Juhlin L (1967) Localization and content of histamine in normal and diseased skin. Acta Derm. Venereol. 47: 383-391.
183. Juhlin L (2004) Inhibition of cold urticaria by desloratadine. J. Dermatol. Treat. 15: 51-59.
184. Kalis B (1996) Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 52 Suppl 1:30-34.
185. Kalivas J, Breneman D, Tharp M, Bruce S and Bigby M (1990) Urticaria: Clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J. Allergy Clin. Immunol. 86: 1014-1018.
186. Kameyoshi Y, Tanaka T, Mihara S, Takahagi S, Niimi N and Hide M (2007) Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: An open study of 21 patients. Br. J. Dermatol. 157: 803-804.
187. Kaplan AP (2002) Chronic urticaria-New concepts regarding pathogenesis and treatment. Curr. Allergy Asthma Rep. 2: 263-264.
188. Kaplan AP and Greaves M (2009) Pathogenesis of chronic urticaria. Clin. Exp. Allergy 39: 777-787.
189. Kaplan AP, Horakova Z and Katz SI (1978) Assessment of tissue fluid histamine levels in patients with urticaria. J. Allergy Clin. Immunol. 61: 350-354.
190. Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST and Georges G (2005) Once-daily fexofenadine treatment for chronic idiopathic urticaria: A multicenter, randomized, double-blind, placebo-controlled study. Ann. Allergy Asthma Immunol. 94: 662-669.
191. Karppinen A, Brummer-Korvenkontio H, Petman L, Kautiainen H, Herve J-P and Reunala T (2006) Levocetirizine for treatment of immediate and delayed mosquito bite reactions. Acta Derm. Venereol. 86: 329-331.
192. Karppinen A, Kautiainen H, Petman L, Burri P and Reunala T (2002) Comparison of ceti-rizine, ebastine and loratadine in the treatment of immediate mosquito-bite allergy. Allergy 57: 534-537.
193. Karppinen A, Petman L, Jekunen A, Kautiainen H, Vaalasti A and Reunala T (2000) Treatment of mosquito bites with ebastine: A field trial. Acta Derm. Venereol. 80: 114-116.
194. Katagiri K, Arakawa S, Hatano Y and Fujiwara S (2006) Fexofenadine, an H1-receptor antag-onist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcy-clopropenone in patients with alopecia areata. J. Dermatol. 33: 75-79.
195. Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D and Berdeaux G (2002) A com-parison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivi-tis. Clin. Ther. 24: 1561-1575.
196. Kato M, Nishida A, Aga Y, Kita J, Kudo Y, Narita H and Endo T (1997) Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent bepotastine besilate. Arzneim. Forsch. 47: 1116-1124.
197. Kavanagh GM, Sabroe RA, Greaves MW and Archer CB (1998) The intradermal effects of the H3 receptor agonist R α methylhistamine in human skin. Br. J. Dermatol. 138: 622-626.
198. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H and Harada S (2003) Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic der-matitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br. J. Dermatol. 148: 1212-1221.
199. Kay GG, Berman B, Mockoviak SH, Morris CE, Reeves D, Starbuck V, Sukenik E and Harris AG (1997) Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch. Intern. Med. 157: 2350-2356.
200. Kay GG and Harris AG (1999) Loratadine: A non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin. Exp. Allergy 29 Suppl 3:147-150.
201. Khan DA (2008) Chronic urticaria: Diagnosis and management. Allergy Asthma Proc. 29: 439-446.
202. Khurana S and Singh P (2006) Rifampin is safe for treatment of pruritus due to chronic cholestasis: A meta-analysis of prospective randomized-controlled trials. Liver Int. 26: 943-948.
203. Kim K, Sussman G, Hebert J, Lumry W, Lutsky B and Gates D (2006) Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 96: 460-465.
204. Kirkegaard J, Secher C, Borum P and Mygind N (1983) Inhibition of histamine-induced nasal symptoms by the H1 antihistamine chlorpheniramine maleate: Demonstration of topical effect. Br. J. Dis. Chest 77: 113-122.
205. Kirkegaard J, Secher C and Mygind N (1982) Effect of the H1 antihistamine chlorpheniramine maleate on histamine-induced symptoms in the human conjunctiva. Indirect evidence for nervous H1 receptors. Allergy 37: 203-208.
206. Klein PA and Clark RAF (1999) An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch. Dermatol. 135: 1522-1525.
207. Koelsche GA, Prickman LE and Carryer HM (1945) The symptomatic treatment of bronchial asthma and hay fever with benadryl. Proc. Staff Meet. Mayo Clin. 20:432.
208. Kojetin DJ, Burris TP, Jensen EV and Khan SA (2008) Implications of the binding of tamoxi-fen to the coactivator recognition site of the estrogen receptor. Endocr.-Relat. Cancer 15: 851-870.
209. Kozel MMA and Sabroe RA (2004) Chronic urticaria: Etiology, management and current and future treatment options. Drugs 64: 2515-2536.
210. Kramer MF, Jordan TR, Klemens C, Hilgert E, Hempel JM, Pfrogner E and Rasp G (2006) Factors contributing to nasal allergic late phase eosinophilia. Am. J. Otolaryngol. 27: 190-199.
211. Kreutner W, Hey JA, Anthes J, Barnett A, Young S and Tozzi S (2000) Preclinical pharma-cology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist: Receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneim. Forsch. 50: 345-352.
212. Kristensen JK, Petersen LJ, Hansen U, Nielsen H, Skov PS and Nielsen HJ (1995) Systemic high-dose ranitidine in the treatment of psoriasis: An open prospective clinical trial. Br. J. Dermatol. 133: 905-908.
213. Krogstad AL, Lonnroth P, Larson G and Wallin BG (1997) Increased interstitial histamine concentration in the psoriatic plaque. J. Invest. Dermatol. 109: 632-635.
214. Kuhne S, Wijtmans M, Lim HD, Leurs R and de Esch IJP (2011) Several down, a few to go: Histamine H3 receptor ligands making the final push towards the market? Expert Opin. Invest. Drugs 20: 1629-1648.
215. Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A and Valiente R (2009) Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal aller-gic rhinitis: A randomized, double-blind, parallel-group study. Clin. Exp. Allergy 39: 1338-1347.
216. Kupczyk M, Kuprys I, Bochenska-Marciniak M, Gorski P and Kuna P (2007) Ranitidine (150 mg daily) inhibits wheal, flare, and itching reactions in skin-prick tests. Allergy Asthma Proc. 28: 711-715.
217. LaForce CF, Corren J, Wheeler WJ and Berger WE (2004) Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexof-enadine. Ann. Allergy Asthma Immunol. 93: 154-159.
218. Lahti A and Haapaniemi T (1993) Initiation of the effects of acrivastine and cetirizine on histamine-induced wheals and itch in human skin. Acta Derm. Venereol. 73: 350-351.
219. LaMotte RH, Shimada SG and Sikand P (2011) Mouse models of acute, chemical itch and pain in humans. Exp. Dermatol. 20: 778-782.
220. Lanier BQ, Finegold I, D’Arienzo P, Granet D, Epstein AB and Ledgerwood GL (2004) Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr. Med. Res. Opin. 20: 1227-1233.
221. Leknes SG, Bantick S, Willis CM, Wilkinson JD, Wise RG and Tracey I (2007) Itch and moti-vation to scratch: An investigation of the central and peripheral correlates of allergen- and histamine-induced itch in humans. J. Neurophysiol. 97: 415-422.
222. Leonardi A, Di SA, Vicari C, Motterle L and Brun P (2011) Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy 66: 1360-1366.
223. Leurs R, Smit MJ, Menge WM and Timmerman H (1994a) Pharmacological characterization of the human histamine H2 receptor stably expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 112: 847-854.
224. Leurs R, Smit MJ, Tensen CP, Ter Laak AM and Timmerman H (1994b) Site-directed mutagen-esis of the histamine H1-receptor reveals a selective interaction of asparagine207 with subclasses of H1-receptor agonists. Biochem. Biophys. Res. Commun. 201: 295-301.
225. Leurs R, Tulp MTM, Menge WMBP, Adolfs MJP, Zuiderveld OP and Timmerman H (1995) Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: An interaction with the 5-HT3 receptor revealed. Br. J. Pharmacol. 116: 2315-2321.
226. Levander S, Haegermark O and Staahle M (1985) Peripheral antihistamine and central seda-tive effects of three H1-receptor antagonists. Eur. J. Clin. Pharmacol. 28: 523-529.
227. Levander S, Staahle-Baeckdahl M and Haegermark O (1991) Peripheral antihistamine and central sedative effects of single and continuous oral doses of cetirizine and hydroxy-zine. Eur. J. Clin. Pharmacol. 41: 435-439.
228. Lewis T (1927) The Blood Vessels of the Human Skin and Their Responses. London: Shaw and Sons.
229. Lewis T (1942) Pain. New York: Macmillan.
230. Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM et al. (2007) BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydro-chloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 recep-tor: Preclinical pharmacology. J. Pharmacol. Exp. Ther. 320: 365-375.
231. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL and Leurs R (2005) Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: Identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol. Exp. Ther. 314: 1310-1321.
232. Lin RY, Curry A, Pesola GR, Knight RJ, Lee HS, Bakalchuk L, Tenenbaum C and Westfal RE (2000) Improved outcomes in patients with acute allergic syndromes who are treated with combined H1 and H2 antagonists. Ann. Emerg. Med. 36: 462-468.
233. Lindahl O (1961) Experimental skin pain induced by injection of water-soluble substances in humans. Acta Physiol. Scand. 51:90 pp.
234. Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L and Fung-Leung W-P (2004) Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br. J. Pharmacol. 142: 161-171.
235. Lippert U, Artuc M, Gruetzkau A, Babina M, Guhl S, Haase I, Blaschke V et al. (2004) Human skin mast cells express H2 and H4, but not H3 receptors. J. Invest. Dermatol. 123: 116-123.
236. Liu C, Ma X-J, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N and Lovenberg TW (2001a) Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59: 420-426.
237. Liu C, Wilson SJ, Kuei C and Lovenberg TW (2001b) Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J. Pharmacol. Exp. Ther. 299: 121-130.
238. Liu YL, Hu FR, Wang IJ, Chen WL and Hou YC (2011) A double-masked study to compare the efficacy and safety of topical cromolyn for the treatment of allergic conjunctivitis. J. Formos Med. Assoc. 110: 690-694.
239. Loew ER and Kaiser ME (1945) Alleviation of anaphylactic shock in guinea pigs with syn-thetic benzohydryl alkamine ethers. Proc. Soc. Exp. Biol. Med. 58: 235-237.
240. Loew ER, Kaiser ME and Moore V (1945) Synthetic benzohydryl alkamine ethers effective in preventing fatal experimental asthma in guinea pigs exposed to atomized histamine. J. Pharmacol. 83: 120-129.
241. Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR and Erlander MG (1999) Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 55: 1101-1107.
242. Lumry W, Prenner B, Corren J and Wheeler W (2007) Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. Ann. Allergy Asthma Immunol. 99: 267-272.
243. Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR and Abelson MB (2010) Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am. J. Ophthalmol. 150: 122-127.
244. Magerl M, Schmolke J, Siebenhaar F, Zuberbier T, Metz M and Maurer M (2007) Acquired cold urticaria symptoms can be safely prevented by ebastine. Allergy 62: 1465-1468.
245. Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV and Bensch G (2007) Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr. Med. Res. Opin. 23: 1445-1452.
246. Manenti L, Tansinda P and Vaglio A (2009) Uraemic pruritus: Clinical characteristics, patho-physiology and treatment. Drugs 69: 251-263.
247. Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ et al. (2006) Effect of oral naltrexone on pruritus in cholestatic patients. World J. Gastroenterol. 12: 1125-1128.
248. Marks R and Greaves MW (1977) Vascular reactions to histamine and compound 48/80 in human skin: Suppression by a histamine H2-receptor blocking agent. Br. J. Clin. Pharmacol. 4: 367-369.
249. Marley PD, Thomson KA, Jachno K and Johnston MJ (1991) Histamine-induced increases in cyclic AMP levels in bovine adrenal medullary cells. Br. J. Pharmacol. 104: 839-846.
250. Matsushita A, Seike M, Okawa H, Kadawaki Y and Ohtsu H (2012) Advantages of histamine H4 receptor antagonist usage with H1 receptor antagonist for the treatment of murine allergic contact dermatitis. Exp. Dermatol. 21: 714-715.
251. Maurer M, Bindslev-Jensen C, Gimenez-Arnau A, Godse K, Grattan CE, Hide M, Kaplan AP et al. (2013) Chronic Idiopathic Urticaria (CIU) is no longer idiopathic: Time for an update! Br. J. Dermatol 168: 455-456.
252. McElin TW and Horton BT (1945) Clinical observations on the use of benadryl; a new anti-histamine substance. Proc. Staff Meet. Mayo Clin. 20: 417-429.
253. McEvoy LK, Smith ME, Fordyce M and Gevins A (2006) Characterizing impaired functional alertness from diphenhydramine in the elderly with performance and neurophysiologic measures. Sleep 29: 957-966.
254. McGavack TH, Elias H and Boyd LJ (1946) Some pharmacological and clinical experiences with dimethylaminoethyl benzhydryl ether hydrochloride (benadryl). Bull. N. Y. Acad. Med. 22:481.
255. Mela M, Mancuso A and Burroughs AK (2003) Review article: Pruritus in cholestatic and other liver diseases. Aliment. Pharmacol. Ther. 17: 857-870.
256. Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE, Finn AF, Jr. et al. (2005) Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 95: 600-606.
257. Meltzer EO, Laforce C, Ratner P, Price D, Ginsberg D and Carr W (2012) MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 33: 324-332.
258. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, Garcia-Rafanell J and Forn J (1997) Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther. 280: 114-121.
259. Meyer N, Paul C and Misery L (2010) Pruritus in cutaneous T-cell lymphomas: Frequent, often severe and difficult to treat. Acta Derm. Venereol. 90: 12-17.
260. Meyrick-Thomas RH, Browne PD and Kirby JDT (1985a) The effect of ranitidine, alone and in combination with clemastine, on allergen-induced cutaneous wheal-and-flare reac-tions in human skin. J. Allergy Clin. Immunol. 76: 864-869.
261. Meyrick-Thomas RH, Browne PD and Kirby JDT (1985b) The influence of ranitidine, alone and in combination with clemastine, on histamine-mediated cutaneous weal and flare reactions in human skin. Br. J. Clin. Pharmacol. 20: 377-382.
262. Miadonna A, Tedeschi A, Leggieri E, Lorini M, Folco G, Sala A, Qualizza R, Froldi M and Zanussi C (1987) Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grass pollen-induced rhinitis. Am. Rev. Respir. Dis. 136: 357-362.
263. Michaelsson G and Juhlin L (1973) Urticaria induced by preservatives and dye additives in food and drugs. Brit. J. Dermatol. 88: 525-532.
264. Mochizuki H, Sadato N, Saito DN, Toyoda H, Tashiro M, Okamura N and Yanai K (2007) Neural correlates of perceptual difference between itching and pain: A human fMRI study. Neuroimage 36: 706-717.
265. Mochizuki H, Tashiro M, Kano M, Sakurada Y, Itoh M and Yanai K (2003) Imaging of cen-tral itch modulation in the human brain using positron emission tomography. Pain 105: 339-346.
266. Mommert S, Gschwandtner M, Koether B, Gutzmer R and Werfel T (2012) Human memory Th17 cells express a functional histamine H4 receptor. Am. J. Pathol. 180: 177-185.
267. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J and Cantilena LR, Jr. (1990) Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 264: 2788-2790.
268. Monroe E, Finn A, Patel P, Guerrero R, Ratner P and Bernstein D (2003) Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 48: 535-541.
269. Monroe EW (1992) Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin. Ther. 14: 17-21.
270. Monti JM (1993) Involvement of histamine in the control of the waking state. Life Sci. 53: 1331-1338.
271. Morita E, Matsuo H and Zhang Y (2005) Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: Suppressive effects on skin response to histamine ionto-phoresis. J. Dermatol. 32: 58-61.
272. Morse KL, Behan J, Laz TM, West RE, Jr., Greenfeder SA, Anthes JC, Umland S et al. (2001) Cloning and characterization of a novel human histamine receptor. J. Pharmacol. Exp. Ther. 296: 1058-1066.
273. Munday J, Bloomfield R, Goldman M, Robey H, Kitowska GJ, Gwiezdziski Z, Wankiewicz A, Marks R, Protas-Drozd F and Mikaszewska M (2002) Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 205: 40-45.
274. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D and Kramer B (2002) Comprehensive evaluation of cetirizine in the management of seasonal allergic rhini-tis: Impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 23: 391-398.
275. Mygind N (1982) Mediators of nasal allergy. J. Allergy Clin. Immunol. 70: 149-159.
276. Mygind N, Secher C and Kirkegaard J (1983) Role of histamine and antihistamines in the nose. Eur. J. Respir. Dis. Suppl. 128 (Pt 1):16-20.
277. Naclerio RM and Togias AG (1991) The nasal allergic reaction: Observations on the role of histamine. Clin. Exp. Allergy 21 Suppl 2:13-19.
278. Nakano Y, Takahashi Y, Ono R, Kurata Y, Kagawa Y and Kamei C (2009) Role of histamine H4 receptor in allergic conjunctivitis in mice. Eur. J. Pharmacol. 608: 71-75.
279. Namdar R and Valdez C (2011) Alcaftadine: A topical antihistamine for use in allergic con-junctivitis. Drugs Today 47: 883-890.
280. Natbony SF, Phillips ME, Elias JM, Godfrey HP and Kaplan AP (1983) Histologic studies of chronic idiopathic urticaria. J. Allergy Clin. Immunol. 71: 177-183.
281. Nettis E, Colanardi MC, Barra L, Ferrannini A, Vacca A and Tursi A (2006) Levocetirizine in the treatment of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Br. J. Dermatol. 154: 533-538.
282. Nielsen HJ, Kristensen JK, Hansen U, Nielsen HI, Skov PS and Petersen LM (1997) Clinical effect of ranitidine in psoriasis. An open prospective study. Ugeskr. Laeger 159: 598-600.
283. Noonan MJ, Raphael GD, Nayak A, Greos L, Olufade AO, Leidy NK, Champan D and Kramer B (2003) The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: A randomized double-blind, placebo-controlled trial. Clin. Exp. Allergy 33: 351-358.
284. Nori M, Iwata S, Munakata Y, Kobayashi H, Kobayashi S, Umezawa Y, Hosono O et al. (2003) Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflamma-tory cytokines. Clin. Exp. Allergy 33: 1544-1554.
285. O’Donoghue M and Tharp MD (2005) Antihistamines and their role as antipruritics. Dermatol. Ther. 18: 333-340.
286. O’Leary PA and Farber EM (1945) Benadryl in the treatment of urticaria. Proc. Staff Meet. Mayo Clin. 20: 429-432.
287. O’Reilly M, Alpert R, Jenkinson S, Gladue RP, Foo S, Trim S, Peter B, Trevethick M and Fidock M (2002) Identification of a histamine H4 receptor on human eosinophils-role in eosinophil chemotaxis. J. Recept. Signal Transduct. 22: 431-448.
288. Oda T, Morikawa N, Saito Y, Masuho Y and Matsumoto S (2000) Molecular cloning and char-acterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 275: 36781-36786.
289. Oei HD (1988) Double-blind comparison of loratadine (SCH 29851), astemizole, and placebo in hay fever with special regard to onset of action. Ann. Allergy 61: 436-439.
290. Ohsawa Y and Hirasawa N (2012) The antagonism of histamine H1 and H4 receptors amelio-rates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 67: 1014-1022.
291. Okamoto T, Iwata S, Ohnuma K, Dang NH and Morimoto C (2009) Histamine H1-receptor antagonists with immunomodulating activities: Potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin. Exp. Immunol. 157: 27-34.
292. Okamura N, Yanai K, Higuchi M, Sakai J, Iwata R, Ido T, Sasaki H, Watanabe T and Itoh M (2000) Functional neuroimaging of cognition impaired by a classical antihista-mine, d-chlorpheniramine. Br. J. Pharmacol. 129: 115-123.
293. Okano M, Fujiwara T, Sugata Y, Gotoh D, Masaoka Y, Sogo M, Tanimoto W et al. (2006) Presence and characterization of prostaglandin D2-related molecules in nasal mucosa of patients with allergic rhinitis. Am. J. Rhinol. 20: 342-348.
294. Ono SJ and Abelson MB (2005) Allergic conjunctivitis: Update on pathophysiology and pros-pects for future treatment. J. Allergy Clin. Immunol. 115: 118-122.
295. Orfeo V, Vardaro A, Lena P, Mensitieri I, Tracey M and De Marco R (2002) Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Eur. J. Ophthalmol. 12: 262-266.
296. Ortonne JP (2011) Chronic urticaria: A comparison of management guidelines. Expert Opin. Pharmacother. 12: 2683-2693.
297. Ortonne JP, Grob JJ, Auquier P and Dreyfus I (2007) Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, multicenter trial. Am. J. Clin. Dermatol. 8: 37-42.
298. Papoiu ADP, Coghill RC, Kraft RA, Wang H and Yosipovitch G (2012) A tale of two itches. Common features and notable differences in brain activation evoked by cowhage and histamine induced itch. Neuroimage 59: 3611-3623.
299. Parrot J-J (1942) Les Modifications Aportees par un Antagoniste de L’histamine (2, 339 R.P.) a la Reaction Vasculaire Locale de la Peau. C. R. Seances Soc. Biol. Ses Fil. 136: 715-716.
300. Paus R, Schmelz M, Biro T and Steinhoff M (2006) Frontiers in pruritus research: Scratching the brain for more effective itch therapy. J. Clin. Invest. 116: 1174-1185.
301. Peiser M, Tralau T, Heidler J, Api AM, Arts JH, Basketter DA, English J et al. (2012) Allergic contact dermatitis: Epidemiology, molecular mechanisms, in vitro methods and regu-latory aspects. Current knowledge assembled at an international workshop at BfR, Germany. Cell. Mol. Life Sci. 69: 763-781.
302. Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW and Port FK (2006) Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 21: 3495-3505.
303. Potter PC (2003) Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 58: 893-899.
304. Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, Nasli Esfahani E and Farrokhi F (2007) Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J. Kidney Dis. 1: 34-37.
305. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA and Nasser SM (2007) BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin. Exp. Allergy 37: 631-650.
306. Preuss H, Ghorai P, Kraus A, Dove S, Buschauer A and Seifert R (2007) Mutations of Cys-17 and Ala-271 in the human histamine H2 receptor determine the species selectivity of guanidine-type agonists and increase constitutive activity. J. Pharmacol. Exp. Ther. 321: 975-982.
307. Raible DG, Lenahan T, Fayvilevich Y, Kosinski R and Schulman ES (1994) Pharmacologic characterization of a novel histamine receptor on human eosinophils. Am. J. Respir. Crit. Care Med. 149: 1506-1511.
308. Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W and Sacks H (2008) Combination therapy with azelastine hydrochloride nasal spray and fluticasone propio-nate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 100: 74-81.
309. Ratner PH, Hampel FC, Amar NJ, van Bavel JH, Mohar D, Marple BF, Roland PS et al. (2005) Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann. Allergy Asthma Immunol. 95: 474-479.
310. Reddy VB, Iuga AO, Shimada SG, LaMotte RH and Lerner EA (2008) Cowhage-evoked itch is mediated by a novel cysteine protease: A ligand of protease-activated receptors. J. Neurosci. 28: 4331-4335.
311. Reunala T, Brummer-Korvenkontio H, Karppinen A, Coulie P and Palosuo T (1993) Treatment of mosquito bites with cetirizine. Clin. Exp. Allergy 23: 72-75.
312. Ring J, Brockow K, Ollert M and Engst R (1999) Antihistamines in urticaria. Clin. Exp. Allergy 29 Suppl 1:31-37.
313. Robertson I and Greaves MW (1978) Responses of human skin blood vessels to synthetic histamine analogs. Br. J. Clin. Pharmacol. 5: 319-322.
314. Rojas-Zamorano JA, Esqueda-Leon E, Jimenez-Anguiano A, Cintra-McGlone L, Mendoza Melendez MA and Velazquez Moctezuma J (2009) The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobi-lization stress in rats. Pharmacol. Biochem. Behav. 91: 291-294.
315. Rosenthal SR and Minard D (1939) Histamine as the chemical mediator for cutaneous pain. J. Exp. Med. 70: 415-425.
316. Rossbach K, Nassenstein C, Gschwandtner M, Schnell D, Sander K, Seifert R, Stark H, Kietzmann M and Baeumer W (2011) Histamine H1, H3 and H4 receptors are involved in pruritus. Neuroscience 190: 89-102.
317. Rossbach K, Wendorff S, Sander K, Stark H, Gutzmer R, Werfel T, Kietzmann M and Baeumer W (2009) Histamine H4 receptor antagonism reduces hapten-induced scratch-ing behaviour but not inflammation. Exp. Dermatol. 18: 57-63.
318. Rothman S (1941) Physiology of itching. Physiol. Rev. 21: 357-381.
319. Rukwied R, Lischetzki G, McGlone F, Heyer G and Schmelz M (2000) Mast cell mediators other than histamine induce pruritus in atopic dermatitis patients. A dermal microdialy-sis study. Br. J. Dermatol. 142: 1114-1120.
320. Russo GE, Spaziani M, Guidotti C, Scarpellini MG, Leri O, Bonini S, Crisciotti C and Carmenini G (1986) Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors). Minerva Urol. Nefrol. 38: 443-447.
321. Saeki H, Furue M, Furukawa F, Hide M, Ohtsuki M, Katayama I, Sasaki R, Suto H and Takehara K (2009) Guidelines for management of atopic dermatitis. J. Dermatol. 36: 563-577.
322. Saitoh T, Fukushima Y, Otsuka H, Ishikawa M, Tamai M, Takahashi H, Mori H et al. (2002) Effects of N-alpha-methyl-histamine on human H2 receptors expressed in CHO cells. Gut 50: 786-789.
323. Salo OP, Harvey SG, Calthrop JG and Gibson JR (1989) A comparison of acrivastine versus hydroxyzine and placebo in the treatment of chronic idiopathic urticaria. J. Int. Med. Res. 17 Suppl 2:18B-21B.
324. Scadding GK, Durham SR, Mirakian R, Jones NS, Leech SC, Farooque S, Ryan D et al. (2008) BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin. Exp. Allergy 38: 19-42.
325. Schechter BA (2008) Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis. Expert Opin. Drug Metab. Toxicol. 4: 507-511.
326. Schmelz M (2001) A neural pathway for itch. Nat. Neurosci. 4: 9-10.
327. Schmelz M, Michael K, Weidner C, Schmidt R, Torebjork HE and Handwerker HO (2000) Which nerve fibers mediate the axon reflex flare in human skin? Neuroreport 11: 645-648.
328. Schmelz M, Schmidt R, Bickel A, Handwerker HO and Torebjork HE (1997) Specific C-receptors for Itch in human skin. J. Neurosci. 17: 8003-8008.
329. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjoerk HE and Handwerker HO (2003) Chemical response pattern of different classes of C-nociceptors to pruritogens and algo-gens. J. Neurophysiol. 89: 2441-2448.
330. Schneider G, Staender S, Burgmer M, Driesch G, Heuft G and Weckesser M (2008) Significant differences in central imaging of histamine-induced itch between atopic dermatitis and healthy subjects. Eur. J. Pain 12: 834-841.
331. Schwartz IF and Iaina A (1999) Uraemic pruritus. Nephrol. Dial. Transplant. 14: 834-839.
332. Secher C, Kirkegaard J, Borum P, Maansson A, Osterhammel P and Mygind N (1982) Significance of H1 and H2 receptors in the human nose: Rationale for topical use of combined antihistamine preparations. J. Allergy Clin. Immunol. 70: 211-218.
333. Seifert R, Wenzel-Seifert K, Burckstummer T, Pertz HH, Schunack W, Dove S, Buschauer A and Elz S (2003) Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J. Pharmacol. Exp. Ther. 305: 1104-1115.
334. Seike M, Furuya K, Omura M, Hamada-Watanabe K, Matsushita A and Ohtsu H (2010) Histamine H4 receptor antagonist ameliorates chronic allergic contact dermatitis induced by repeated challenge. Allergy 65: 319-326.
335. Shamsi Z and Hindmarch I (2000) Sedation and antihistamines: A review of inter-drug dif-ferences using proportional impairment ratios. Human Psychopharmacol. 15:S3-S30.
336. Sharif NA, Xu SX and Yanni JM (1996) Olopatadine (AL-4943A): ligand binding and func-tional studies on a novel, long-acting, H1-selective histamine antagonist and antiallergic agent for use in allergic conjunctivitis. J. Ocul. Pharmacol. Ther. 12: 401-407.
337. Shelley WB and Arthur RP (1955) Mucunain, the active pruritogenic proteinase of cowhage. Science 122: 469-470.
338. Shelley WB and Melton FM (1950) Relative effect of local anesthetics on experimental hista-mine pruritus in man. J. Invest. Dermatol. 15: 299-300.
339. Shelton D and Eiser N (1994) Histamine receptors in the human nose. Clin. Otolaryngol. Allied Sci. 19: 45-49.
340. Shimada SG and LaMotte RH (2008) Behavioral differentiation between itch and pain in mouse. Pain 139: 681-687.
341. Shin N, Covington M, Bian D, Zhuo J, Bowman K, Li Y, Soloviev M et al. (2012) INCB38579, a novel and potent histamine H4 receptor small molecule antagonist with anti-inflammatorypain and anti-pruritic functions. Eur. J. Pharmacol. 675: 47-56.
342. Siebenhaar F, Degener F, Zuberbier T, Martus P and Maurer M (2009) High-dose deslorata-dine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 123: 672-679.
343. Sikand P, Shimada SG, Green BG and LaMotte RH (2009) Similar itch and nociceptive sensa-tions evoked by punctate cutaneous application of capsaicin, histamine and cowhage. Pain 144: 66-75.
344. Simone DA, Zhang X, Li J, Zhang J-M, Honda CN, LaMotte RH and Giesler GJ, Jr. (2004) Comparison of responses of primate spinothalamic tract neurons to pruritic and algo-genic stimuli. J. Neurophysiol. 91: 213-222.
345. Simons FE (2004) Advances in H1-antihistamines. N. Engl. J. Med. 351: 2203-2217.
346. Simons FER and Simons KJ (2011) Histamine and H1-antihistamines: Celebrating a century of progress. J. Allergy Clin. Immunol. 128:1139-1150.e1134.
347. Simpson RJ (1994) Budesonide and terfenadine, separately and in combination, in the treat-ment of hay fever. Ann. Allergy 73: 497-502.
348. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Finlay AY et al. (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br. J. Dermatol. 161: 987-1019.
349. Sollmann T and Pilcher JD (1917) Endermic reactions. I. J. Pharmacol. 9: 309-340.
350. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, Alenius H et al. (2006) IL-31: A new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 117: 411-417.
351. Spangler DL, Abelson MB, Ober A and Gotnes PJ (2003) Randomized, double-masked com-parison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin. Ther. 25: 2245-2267.
352. Spangler DL, Bensch G and Berdy GJ (2001) Evaluation of the efficacy of olopatadine hydro-chloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin. Ther. 23: 1272-1280.
353. Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, Church DS, Dimitrov V and Church MK (2010) The effectiveness of levocetirizine and deslorata-dine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 125: 676-682.
354. Staub AM and Bovet D (1937) Action of thymoxyethyldiethylamine (F 929) and other phenol ethers on anaphylactic shock in guinea pigs. C. R. Seances Soc. Biol. Fil. 125: 818-821.
355. Stokes JR, Romero FA, Jr., Allan RJ, Phillips PG, Hackman F, Misfeldt J and Casale TB (2012) The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J. Allergy Clin. Immunol. 129:409-412.e402.
356. Storms WW, Bodman SF, Nathan RA, Chervinsky P, Banov CH, Dockhorn RJ, Jarmoszuk I et al. (1989) SCH 434: A new antihistamine/decongestant for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 83: 1083-1090.
357. Strakhova MI, Nikkel AL, Manelli AM, Hsieh GC, Esbenshade TA, Brioni JD and Bitner RS (2009) Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res. 1250: 41-48.
358. Sugimoto Y, Iba Y, Nakamura Y, Kayasuga R and Kamei C (2004) Pruritus-associated response mediated by cutaneous histamine H3 receptors. Clin. Exp. Allergy 34: 456-459.
359. Supramaniam G and Warner JO (1986) Artificial food additive intolerance in patients with angio-oedema and urticaria. Lancet 2: 907-909.
360. Suwa E, Yamaura K, Oda M, Namiki T and Ueno K (2011) Histamine H4 receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. Eur. J. Pharmacol. 667: 383-388.
361. Takahashi Y, Kagawa Y, Izawa K, Ono R, Akagi M and Kamei C (2009) Effect of histamine H4 receptor antagonist on allergic rhinitis in mice. Int. Immunopharmacol. 9: 734-738.
362. Takaoka A, Arai I, Sugimoto M, Yamaguchi A, Tanaka M and Nakaike S (2005) Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur. J. Pharmacol. 516: 180-181.
363. Tamura T, Matsubara M, Amano T and Chida M (2008) Olopatadine ameliorates rat experi-mental cutaneous inflammation by improving skin barrier function. Pharmacology 81: 118-126.
364. Tanizaki H, Ikoma A, Fukuoka M, Miyachi Y and Kabashima K (2012) Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. Int. Arch. Allergy Immunol. 158: 191-195.
365. Taylor-Clark T, Sodha R, Warner B and Foreman J (2005) Histamine receptors that influence blockage of the normal human nasal airway. Br. J. Pharmacol. 144: 867-874.
366. Thakkar MM (2011) Histamine in the regulation of wakefulness. Sleep Med. Rev. 15: 65-74.
367. Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung W-P, Hofstra CL, Jiang W, Nguyen S et al. (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J. Pharmacol. Exp. Ther. 309: 404-413.
368. Thurmond RL, Gelfand EW and Dunford PJ (2008) The role of histamine H1 and H4 recep-tors in allergic inflammation: The search for new antihistamines. Nat. Rev. Drug Discov. 7: 41-53.
369. Torkildsen G and Shedden A (2011) The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr. Med. Res. Opin. 27: 623-631.
370. Tran VT, Chang RS and Snyder SH (1978) Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine. Proc. Natl. Acad. Sci. USA 75: 6290-6294.
371. Trendelenburg U and Hobbs RD (1960) Action of histamine and 5-hydroxytryptamine (5-HT) on isolated mammalian atria. J. Pharmacol. Exp. Ther. 130: 450-460.
372. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC and Zylicz Z (2003) Itch: Scratching more than the surface. QJM 96: 7-26.
373. Uehara M (1982) Reduced histamine reaction in atopic dermatitis. Arch. Dermatol. 118: 244-245.
374. Wagenmann M, Schumacher L and Bachert C (2005) The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 60: 1132-1138.
375. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, Lang DM et al. (2008) The diagnosis and management of rhinitis: An updated practice parameter. J. Allergy Clin. Immunol. 122:S1-S84.
376. Wang DY, Hanotte F, De VC and Clement P (2001) Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy (Cph) 56: 339-343.
377. Wang YH, Tache Y, Harris AG, Kreutner W, Daly AF and Wei JY (2005) Desloratadine pre-vents compound 48/80-induced mast cell degranulation: Visualization using a vital fluo-rescent dye technique. Allergy 60: 117-124.
378. Weiner JM, Abramson MJ and Puy RM (1998) Intranasal corticosteroids versus oral H1 recep-tor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. Br. Med. J. 317: 1624-1629.
379. Weisler RH, Pandina GJ, Daly EJ, Cooper K and Gassmann-Mayer C (2012) Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 26: 421-434.
380. Weisshaar E, Ziethen B and Gollnick H (1997) Can a serotonin type 3 (5-HT3) receptor antag-onist reduce experimentally-induced itch? Inflamm. Res. 46: 412-416.
381. Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR and Weiner DM (2002) Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacology 42: 929-940.
382. Weller K and Maurer M (2009) Desloratadine inhibits human skin mast cell activation and histamine release. J. Invest. Dermatol. 129: 2723-2726.
383. Wells JA, Bull HB, Dragstedt CA, Morris HC (1945) Observations on the nature of the antagonism of histamine by beta-dimethylaminoethyl benzhydryl ether (benadryl). J. Pharmacol. Exp. Ther. 85: 122-128.
384. Whitcup SM, Bradford R, Lue J, Schiffman RM and Abelson MB (2004) Efficacy and tol-erability of ophthalmic epinastine: A randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic con-junctivitis. Clin. Ther. 26: 29-34.
385. Wieland K, Bongers G, Yamamoto Y, Hashimoto T, Yamatodani A, Menge WMBP, Timmerman H, Lovenberg TW and Leurs R (2001) Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: Display of agonism and inverse ago-nism by H3 antagonists. J. Pharmacol. Exp. Ther. 299: 908-914.
386. Wiesner RH, LaRusso NF, Ludwig J and Dickson ER (1985) Comparison of the clinico-pathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 88: 108-114.
387. Williams HC (2005) Clinical practice. Atopic dermatitis. N. Engl. J. Med. 352: 2314-2324.
388. Wilson AM, Haggart K, Sims EJ and Lipworth BJ (2002) Effects of fexofenadine and deslo-ratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin. Exp. Allergy 32: 1504-1509.
389. Windaus A and Vogt W (1907) Synthese des Imidazolyl-athylamins. Ber. Dtsch. Chem. Ges. 40: 3691-3695.
390. Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M and Van Buuren HR (1997) Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 113: 1264-1269.
391. Wong L, Hendeles L and Weinberger M (1981) Pharmacologic prophylaxis of allergic rhini-tis: Relative efficacy of hydroxyzine and chlorpheniramine. J. Allergy Clin. Immunol. 67: 223-228.
392. Wood-Baker R, Lau L and Howarth PH (1996) Histamine and the nasal vasculature: The influence of H1 and H2-histamine receptor antagonism. Clin. Otolaryngol. Allied Sci. 21: 348-352.
393. Woosley RL (1996) Cardiac actions of antihistamines. Ann. Rev. Pharmacol. Toxicol. 36: 233-252.
394. Wulff BS, Hastrup S and Rimvall K (2002) Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur. J. Pharmacol. 453: 33-41.
395. Wyllie JH, Hesselbo T and Black JW (1972) Effects in man of histamine H2-receptor blockade by burimamide. Lancet 2: 1117-1120.
396. Yamaura K, Oda M, Suwa E, Suzuki M, Sato H and Ueno K (2009) Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J. Toxicol. Sci. 34: 427-431.
397. Yanez A and Rodrigo GJ (2002) Intranasal corticosteroids versus topical H1 receptor antago-nists for the treatment of allergic rhinitis: A systematic review with meta-analysis. Ann. Allergy Asthma Immunol. 89: 479-484.
398. Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C and Ozden S (2003) Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac trometh-amine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol. Scand. 81: 378-382.
399. Yosipovitch G, Ansari N, Goon A, Chan YH and Goh CL (2002) Clinical characteristics of pruritus in chronic idiopathic urticaria. Br. J. Dermatol. 147: 32-36.
400. Yosipovitch G, Duque MI, Fast K, Dawn AG and Coghill RC (2007) Scratching and nox-ious heat stimuli inhibit itch in humans: A psychophysical study. Br. J. Dermatol. 156: 629-634.
401. Yosipovitch G, Fast K and Bernhard JD (2005) Noxious heat and scratching decrease hista-mine-induced itch and skin blood flow. J. Invest. Dermatol. 125: 1268-1272.
402. Yosipovitch G, Goon A, Wee J, Chan YH and Goh CL (2000) The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br. J. Dermatol. 143: 969-973.
403. Yosipovitch G, Greaves MW and Schmelz M (2003) Itch. Lancet 361: 690-694.
404. Yu F, Wolin RL, Wei J, Desai PJ, McGovern PM, Dunford PJ, Karlsson L and Thurmond RL (2010) Pharmacological characterization of oxime agonists of the histamine H4 recep-tor. J. Receptor Ligand Channel Res. 3: 37-49.
405. Zackheim HS, Kashani-Sabet M and Amin S (1998) Topical corticosteroids for mycosis fun-goides. Experience in 79 patients. Arch. Dermatol. 134: 949-954.
406. Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J and Andrews M (1997) Electrocardiographic findings in patients with diphenhydramine overdose. Am. J. Cardiol. 80: 1168-1173.
407. Zazzali JL, Broder MS, Chang E, Chiu MW and Hogan DJ (2012) Cost, utilization, and patterns of medication use associated with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol. 108: 98-102.
408. Zhu Y, Michalovich D, Wu H, Tan KB, Dytko GM, Mannan IJ, Boyce R et al. (2001) Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol. Pharmacol. 59: 434-441.
409. Zonneveld IM, Meinardi MM, Karlsmark T, Johansen UB, Kuiters GR, Hamminga L, Staberg B et al. (1997) Ranitidine does not affect psoriasis: A multicenter, double-blind, placebo-controlled study. J. Am. Acad. Dermatol. 36: 932-934.
410. Zuber P and Pecoud A (1988) Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens. J. Allergy Clin. Immunol. 82: 590-594.
411. Zuberbier T (2012) Pharmacological rationale for the treatment of chronic urticaria with sec-ond-generation non-sedating antihistamines at higher-than-standard doses. J. Eur. Acad. Dermatol. Venereol. 26: 9-18.
412. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Gimenez-Arnau AM, Grattan CE et al. (2009) EAACI/GA(2)LEN/EDF/WAO guideline: Management of urticaria. Allergy 64: 1427-1443.
413. Zuberbier T, Chantraine-Hess S, Hartmann K and Czarnetzki BM (1995) Pseudoallergen-free diet in the treatment of chronic urticaria. A prospective study. Acta Derm. Venereol. 75: 484-487.
414. Zuberbier T and Maurer M (2007) Urticaria: Current opinions about etiology, diagnosis and therapy. Acta Derm. Venereol. 87: 196-205.
415. Zuberbier T and Maurer M (2010) Antihistamines in the treatment of urticaria. Adv. Exp. Med. Biol. 709: 67-72.
416. Zucker I, Yosipovitch G, David M, Gafter U and Boner G (2003) Prevalence and charac-terization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J. Am. Acad. Dermatol. 49: 842-846.